News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI
Dana-Farber Cancer Institute/dana-farber.org
Nov 26, 2024, 17:58

Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI

Dana-Farber’s Breast Oncology Center shared a post on X:

“We are leading a phase 2 study, called TRUDI, to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn if the intervention works in stage III, HER2-expressing Inflammatory Breast Cancer.”

Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI

Read further.

More featuring Dana-Farber’s Breast Oncology Center.

cancer Dana-Farber’s Breast Oncology Center Durvalumab inflammatory breast cancer OncoDaily Oncology Trastuzumab deruxtecan TRUDI
Special Coverage
Blog
Jun 11, 2025, 07:30
Raphael E. Cuomo: My New Book "Crave: The Hidden Biology of Addiction and Cancer" is Now Published
Blog
Jun 11, 2025, 07:21
Registration is Open for BSMO Webinar on Radioligand Therapy!
Blog
Jun 11, 2025, 07:16
Lung Cancer Research Foundation Announces Expansion of Its Research Advocates Program
Blog
Jun 11, 2025, 07:07
St. Elizabeth Healthcare Was Recognized as One of America’s Best Hospitals for Specialized Care 2025 by Newsweek!
Blog
Jun 11, 2025, 07:00
Jeffrey Velotta Shared His Work on Improving Lung Cancer Screening Uptake in Asian Americans - LUNGevity Foundation
Blog
Jun 11, 2025, 06:58
Zainab Shinkafi-Bagudu Highlights Nigeria's Official Launch of PECCiN to Eliminate Cervical Cancer
Blog
Jun 11, 2025, 06:50
Registration is Open for SPCC's Webinar on Early Nutrition Screening and Intervention in Cancer Care
Blog
Jun 11, 2025, 06:42
UICC Leaders Cary Adams and Ulrika Årehed Kågström Highlight Cancer Priorities for 2025–2026
Blog
Jun 11, 2025, 06:37
Early-bird Registration is Now Open for the ACCC 42nd National Oncology Conference
Blog
Jun 11, 2025, 06:29
Andreas Charalambous Shares Updates on TRANSiTION Project Training Pathways and Synergy with SUSA
Blog
Jun 11, 2025, 06:20
Antonio Passaro: Overall Survival in EGFR-Mutant Advanced NSCLC Treated with First-Line Osimertinib
Blog
Jun 11, 2025, 06:11
Yeva Margaryan: The Economist Impact’s 10th Annual World Cancer Series Europe has Officially Begun!